Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis.

Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME, Semenza GL.

J Mol Med (Berl). 2012 Jul;90(7):803-15. doi: 10.1007/s00109-011-0855-y.

2.

Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators.

Hamsa TP, Kuttan G.

Drug Chem Toxicol. 2012 Jan;35(1):57-70. doi: 10.3109/01480545.2011.589437.

PMID:
22145808
3.

FDA cancels approval for bevacizumab in advanced breast cancer.

Tanne JH.

BMJ. 2011 Nov 25;343:d7684. doi: 10.1136/bmj.d7684. No abstract available.

PMID:
22121166
4.

Molecular pathways: targeting proteasomal protein degradation in cancer.

Molineaux SM.

Clin Cancer Res. 2012 Jan 1;18(1):15-20. doi: 10.1158/1078-0432.CCR-11-0853.

5.

Metabolic regulation of hematopoietic stem cells in the hypoxic niche.

Suda T, Takubo K, Semenza GL.

Cell Stem Cell. 2011 Oct 4;9(4):298-310. doi: 10.1016/j.stem.2011.09.010. Review.

6.

Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation.

Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong CM, Khoo US, Ng IO, Wirtz D, Semenza GL.

Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16369-74. doi: 10.1073/pnas.1113483108.

7.

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.

Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, Papandreou CN, Liakos P.

J Mol Med (Berl). 2012 Jan;90(1):45-54. doi: 10.1007/s00109-011-0805-8. Erratum in: J Mol Med (Berl). 2013 Jun;91(6):771-3.

PMID:
21909688
8.

Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition.

Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC, Teng SC, Wu KJ.

Mol Cell. 2011 Sep 2;43(5):811-22. doi: 10.1016/j.molcel.2011.07.012.

9.

HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs.

Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B, Winnard PT Jr, Raman V, Zhen L, Mitzner WA, Sukumar S, Semenza GL.

Oncogene. 2012 Apr 5;31(14):1757-70. doi: 10.1038/onc.2011.365.

10.

Oxygen sensing, homeostasis, and disease.

Semenza GL.

N Engl J Med. 2011 Aug 11;365(6):537-47. doi: 10.1056/NEJMra1011165. Review. No abstract available. Erratum in: N Engl J Med. 2011 Sep 8;365(10):968.

PMID:
21830968
11.

Regulation of metabolism by hypoxia-inducible factor 1.

Semenza GL.

Cold Spring Harb Symp Quant Biol. 2011;76:347-53. doi: 10.1101/sqb.2011.76.010678. Review.

PMID:
21785006
12.

HIF induces human embryonic stem cell markers in cancer cells.

Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, Tewari M, Liu A, Vessella R, Rostomily R, Born D, Horwitz M, Ware C, Blau CA, Cleary MA, Rich JN, Ruohola-Baker H.

Cancer Res. 2011 Jul 1;71(13):4640-52. doi: 10.1158/0008-5472.CAN-10-3320.

13.

Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.

Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G.

Clin Cancer Res. 2011 Aug 1;17(15):5123-31. doi: 10.1158/1078-0432.CCR-11-0682.

14.

Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1.

Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Semenza GL.

Cell. 2011 May 27;145(5):732-44. doi: 10.1016/j.cell.2011.03.054.

15.

Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

Wang Y, Liu Y, Malek SN, Zheng P, Liu Y.

Cell Stem Cell. 2011 Apr 8;8(4):399-411. doi: 10.1016/j.stem.2011.02.006.

16.

Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

Rohwer N, Cramer T.

Drug Resist Updat. 2011 Jun;14(3):191-201. doi: 10.1016/j.drup.2011.03.001. Review.

PMID:
21466972
17.

High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.

Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR.

Blood. 2011 Jun 9;117(23):e207-17. doi: 10.1182/blood-2010-10-314427.

18.

Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue.

Rey S, Luo W, Shimoda LA, Semenza GL.

Blood. 2011 May 5;117(18):4988-98. doi: 10.1182/blood-2010-11-321190.

19.

Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression.

Carbonaro M, O'Brate A, Giannakakou P.

J Cell Biol. 2011 Jan 10;192(1):83-99. doi: 10.1083/jcb.201004145.

20.

Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase.

Kim YH, Coon A, Baker AF, Powis G.

Cancer Chemother Pharmacol. 2011 Aug;68(2):405-13. doi: 10.1007/s00280-010-1500-0.

Items per page

Supplemental Content

Support Center